You have free access to this content

Cancer

Cover image for Vol. 117 Issue 20

15 October 2011

Volume 117, Issue 20

Pages 4573–4805

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Tackling overtreatment of prostate cancer : The role of comorbidity (pages 4576–4578)

      Jennifer Beebe-Dimmer and Vahakn Shahinian

      Version of Record online: 8 APR 2011 | DOI: 10.1002/cncr.26106

      Despite calls for more conservative management of localized prostate cancer in both the published literature and in practice guidelines, overtreatment remains rampant. The troubling implication is that, unless prediction tools are virtually perfect in their ability to discern which men will or will not die from their prostate cancer, patients may continue to choose aggressive interventions.

    2. You have free access to this content
      A phase 2 trial of complete resection for stage IV melanoma : Results of Southwest Oncology Group Clinical Trial S9430 (pages 4579–4581)

      David W. Ollila

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26118

      This is a concise editorial looking at the evidence for metastasectomy in stage IV melanoma patients. This includes an updated review of the Southwest Oncology Group data.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      The role of [18F]-2-fluoro-2-deoxy-d-glucose–positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy : Systematic review and meta-analysis of the literature (pages 4582–4594)

      Dennis Vriens, Johannes H. W. de Wilt, Gert J. van der Wilt, Romana T. Netea-Maier, Wim J. G. Oyen and Lioe Fee de Geus-Oei

      Version of Record online: 22 MAR 2011 | DOI: 10.1002/cncr.26085

      • original image
      • original image
      • original image
      • original image
      • original image

      In this meta-analysis of 6 studies including 225 patients with thyroid nodules with indeterminate fine-needle aspiration biopsy results, [18F]-2-fluoro-2-deoxy-D-glucose–positron emission tomography (FDG-PET) proved an excellent discriminator of which patients would not benefit from diagnostic surgery, because the negative predictive value of FDG-PET for ruling out thyroid cancer was 96%.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women (pages 4595–4605)

      Shervin M. Shirvani, I-Wen Pan, Thomas A. Buchholz, Ya-Chen Tina Shih, Karen E. Hoffman, Sharon H. Giordano and Benjamin D. Smith

      Version of Record online: 27 JUN 2011 | DOI: 10.1002/cncr.26081

      • original image

      In this analysis of the Surveillance, Epidemiology, and End Results-Medicare cohort, trends in postmastectomy radiation use in response to evidence-based guideline publication were measured among elderly patients with high-risk breast cancer. In this population, postmastectomy radiation therapy (PMRT) use did not increase after the release of evidence-based guidelines, and nearly 50% of high-risk breast cancer patients did not receive PMRT during the study period.

    2. You have free access to this content
      Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy (pages 4606–4616)

      Vaclav Pecha, Dusan Kolarik, Renata Kozevnikova, Karolina Hovorkova, Petruse Hrabetova, Michael Halaska, Oldrich Sottner, Marketa Trnkova, Lubos Petruzelka and Hana Kolarova

      Version of Record online: 22 MAR 2011 | DOI: 10.1002/cncr.26102

      The study presents a retrospective analysis of 343 patients with primary breast cancer treated with neoadjuvant chemotherapy who underwent sentinel lymph node biopsy (SLNB). With the present technique, SLNB cannot be recommended as a reliable predictor of axillary lymph node status when performed after neoadjuvant chemotherapy.

    3. Endocrine Disease
      You have free access to this content
      Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy (pages 4617–4622)

      Staffan Welin, Halfdan Sorbye, Sigrunn Sebjornsen, Stian Knappskog, Christian Busch and Kjell Öberg

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26124

      • original image
      • original image

      In poorly differentiated endocrine carcinoma, treatment with temozolomide had good effect and was well tolerated as second-line treatment.

    4. Gastrointestinal Disease
      You have free access to this content
      Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer (pages 4623–4632)

      Ben Tran, Scott Kopetz, Jeanne Tie, Peter Gibbs, Zhi-Qin Jiang, Christopher H. Lieu, Atin Agarwal, Dipen M. Maru, Oliver Sieber and Jayesh Desai

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26086

      • original image
      • original image

      A large retrospective study of patients from Royal Melbourne Hospital (Australia) and The University of Texas MD Anderson Cancer Center (USA) analyzed the impact of BRAF and microsatellite instability (MSI) in metastatic colorectal cancer (CRC). The major findings include a distinct pattern of metastatic spread in BRAF mutant tumors (increased rates of peritoneal and distant lymph node metastases and reduced rates of lung metastases) and significantly poorer survival observed in MSI tumors, although this survival difference was not evident in the BRAF mutant population, further confirming BRAF mutation as a significant poor prognostic factor in metastatic CRC.

    5. You have free access to this content
      Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor (pages 4633–4641)

      Akira Sawaki, Toshirou Nishida, Toshihiko Doi, Yasuhide Yamada, Yoshito Komatsu, Tatsuo Kanda, Yoshihiro Kakeji, Yusuke Onozawa, Makoto Yamasaki and Atsushi Ohtsu

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26120

      • original image
      • original image
      • original image
      • original image

      In this phase 2 study, the efficacy and safety of nilotinib (AMN107) as a third-line therapy for patients with gastrointestinal stromal tumors was evaluated. Nilotinib was well tolerated and demonstrated encouraging antitumor activity; 23 (66%) patients had stable disease (≥6 weeks) as the best response, and 1 (3%) patient had a confirmed partial response.

    6. Genitourinary Disease
      You have free access to this content
      Comorbidity and competing risks for mortality in men with prostate cancer (pages 4642–4650)

      Timothy J. Daskivich, Karim Chamie, Lorna Kwan, Jessica Labo, Atreya Dash, Sheldon Greenfield and Mark S. Litwin

      Version of Record online: 8 APR 2011 | DOI: 10.1002/cncr.26104

      • original image
      • original image

      Comorbidity is a key component in prostate cancer decision making but is poorly integrated because of lack of a standardized comorbidity assessment tool. The authors found that men with Charlson scores 3+ and low-risk to intermediate-risk tumors had an exceedingly high risk of death from other causes and a low risk of prostate cancer mortality, suggesting that such men should strongly consider conservative over aggressive treatment for their prostate cancer.

    7. You have free access to this content
      Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer (pages 4651–4658)

      Matthew H. Hayn, Heather Orom, Vickie L. Shavers, Martin G. Sanda, Mark Glasgow, James L. Mohler and Willie Underwood III

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26103

      The receipt of pelvic lymph node dissection (PLND) is recommended for men who are diagnosed with high-risk prostate cancer (Gleason score ≥8). In this study, among men who were diagnosed with high-risk prostate cancer, black men were less likely to undergo PLND than white men.

    8. Head and Neck Disease
      You have free access to this content
      Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma (pages 4659–4670)

      Gerhard F. Huber, Andrea Albinger-Hegyi, Alex Soltermann, Matthias Roessle, Nicole Graf, Stephan K. Haerle, David Holzmann, Holger Moch and Ivan Hegyi

      Version of Record online: 29 MAR 2011 | DOI: 10.1002/cncr.26100

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      B-cell–specific Moloney murine leukemia virus integration site 1 (Bmi-1) expression and the absence of p16 expression were correlated negatively with disease-specific survival and recurrence-free survival in patients with oropharyngeal cancer. The results from this study indicated that Bmi-1 and p16 may have value as predictive markers in combination with other factors to select patients for more aggressive treatment and follow-up.

    9. You have free access to this content
      Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation (pages 4671–4678)

      Kevin S. Choe, Daniel J. Haraf, Abhishek Solanki, Ezra E. W. Cohen, Tanguy Y. Seiwert, Kerstin M. Stenson, Elizabeth A. Blair, Louis Portugal, Victoria M. Villaflor, Mary Ellyn Witt, Everett E. Vokes and Joseph K. Salama

      Version of Record online: 13 JUN 2011 | DOI: 10.1002/cncr.26084

      • original image
      • original image

      For patients with recurrent head and neck cancer in a previously irradiated area, concomitant chemotherapy with reirradiation is a treatment option that offers a small but real chance of cure in select patients. The results of the current study indicate that previous treatment with chemoradiotherapy was an important pretreatment characteristic and was associated with poor survival.

    10. Hematologic Malignancies
      You have free access to this content
      Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia : Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome (pages 4679–4688)

      Issa F. Khouri, Roland Bassett, Nancy Poindexter, Susan O'Brien, Carlos E. Bueso-Ramos, Yvonne Hsu, Alessandra Ferrajoli, Michael J. Keating, Richard Champlin and Marcelo Fernandez-Vina

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26091

      • original image
      • original image
      • original image

      The authors found that immunoglobulin G and CD4 levels are predictive of survival after nonmyeloablative allogeneic transplantation for chronic lymphocytic leukemia and that human leukocyte antigen alleles predict response to immunomanipulation.

    11. You have free access to this content
      Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia (pages 4689–4695)

      Sergej Konoplev, Jeffrey L. Jorgensen, Deborah A. Thomas, E Lin, Jan Burger, Hagop M. Kantarjian, Michael Andreeff, L. Jeffrey Medeiros and Marina Konopleva

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26113

      • original image
      • original image

      CXC chemokine receptor 4 (CXCR4) is activated by phosphorylation (pCXCR4) and is essential for the migration of hematopoietic precursors to bone marrow. The results from this study indicate that the assessment of pCXCR4 has prognostic significance in adult patients with B-acute lymphoblastic leukemia.

    12. You have free access to this content
      Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling (pages 4696–4706)

      Violaine Havelange, Nicole Stauffer, Catherine C. E. Heaphy, Stefano Volinia, Michael Andreeff, Guido Marcucci, Carlo M. Croce and Ramiro Garzon

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26096

      • original image
      • original image
      • original image
      • original image

      Integration of microRNA and messenger RNA expression profiling provided insight into functional microRNA–messenger RNA interactions in acute myeloid leukemia. Such interactions could be targeted therapeutically in this disease.

    13. Lung Disease
      You have free access to this content
      Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer (pages 4707–4713)

      Joe Y. Chang, Ritsuko Komaki, Charles Lu, Hong Y. Wen, Pamela K. Allen, Anne Tsao, Michael Gillin, Radhe Mohan and James D. Cox

      Version of Record online: 22 MAR 2011 | DOI: 10.1002/cncr.26080

      • original image

      Standard therapy for stage III nonsmall cell lung cancer, concurrent chemoradiation therapy with photon (x-ray–based) therapy, is associated with significant toxicity and produces suboptimal local control. The authors found that concurrent chemotherapy and high-dose proton beam therapy was less toxic than conventional photon-based treatments and produced a total local failure rate of 20.5%.

    14. You have free access to this content
      Functionally significant nicotine acetylcholine receptor subunit α5 promoter haplotypes are associated with susceptibility to lung cancer in Chinese (pages 4714–4723)

      Xia Zheng, Wenyuan Duan, Jing Xu, Chenxia Nie, Zhangmin Yang, Hongyan Wang, Weimin Wang and Daru Lu

      Version of Record online: 29 MAR 2011 | DOI: 10.1002/cncr.26017

      • original image
      • original image
      • original image

      The results from this study indicated a new associated risk pattern between nicotine acetylcholine receptor subunit α5 (CHRNA5) promoter activity and susceptibility to lung cancer that implies a complex role of the CHRNA5 gene in lung cancer. Together, the findings confirm CHRNA5 as a lung cancer susceptibility gene in the Chinese population.

    15. You have free access to this content
      Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer (pages 4724–4731)

      Sirisha Jonnalagadda, Jacqueline Arcinega, Cardinale Smith and Juan P. Wisnivesky

      Version of Record online: 30 MAR 2011 | DOI: 10.1002/cncr.26093

      • original image
      • original image

      The results from this study validated the lymph node ratio as an independent prognostic factor of survival in patients with N1 nonsmall cell lung cancer. This information may be used to identify patients who require aggressive postoperative management and increased surveillance, because they are at greater risk of cancer recurrence.

    16. Melanoma
      You have free access to this content
      A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma (pages 4732–4739)

      John M. Kirkwood, Rene Gonzalez, Douglas Reintgen, Philip R. Clingan, Robert R. McWilliams, Dinesh P. de Alwis, Annamaria Zimmermann, Michael P. Brown, Robert L. Ilaria Jr and Michael J. Millward

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26068

      • original image
      • original image
      • original image

      Tasisulam, a novel antineoplastic agent, was administered intravenously on Day 1 of 21-day cycles according to a lean body weight-based dosing algorithm targeting a peak plasma concentration of 420 μg/mL. Tasisulam demonstrated antitumor activity and tolerable toxicity as second-line treatment in patients with metastatic melanoma.

    17. You have free access to this content
      A phase 2 trial of complete resection for stage IV melanoma : Results of Southwest Oncology Group Clinical Trial S9430 (pages 4740–4706)

      Jeffrey A. Sosman, James Moon, Ralph J. Tuthill, James A. Warneke, John T. Vetto, Bruce G. Redman, P. Y. Liu, Joseph M. Unger, Lawrence E. Flaherty and Vernon K. Sondak

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26111

      • original image
      • original image
      • original image

      One of the only prospective analyses of surgery for metastatic disease in patients with stage IV disease, this article reports on a multicenter cooperative group trial with enrollment of patients from 18 different institutions. Incorporating consistent monitoring is a hallmark of cooperative group trials.

    18. You have free access to this content
      Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma : A 20-year experience (pages 4747–4755)

      Patrick Kelly, Gunar K. Zagars, Jancie N. Cormier, Merrick I. Ross and B. Ashleigh Guadagnolo

      Version of Record online: 28 MAR 2011 | DOI: 10.1002/cncr.26088

      • original image
      • original image
      • original image

      The authors report their 20-year experience with sphincter-sparing excision combined with radiation therapy for the treatment of localized anorectal melanoma. The results indicated that sphincter-sparing local excision with adjuvant radiation therapy is a well-tolerated approach that provides effective local control for these patients.

    19. Sarcoma
      You have free access to this content
      Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival (pages 4756–4763)

      Steven C. Katz, Keith Baldwin, Giorgos Karakousis, Nicole Moraco, Anthony Buglino, Samuel Singer and Murray F. Brennan

      Version of Record online: 4 APR 2011 | DOI: 10.1002/cncr.26105

      • original image
      • original image
      • original image

      The authors report an unusual association between soft tissue sarcoma (STS) and lymphoma. STS arising in those diagnosed with lymphoma was more likely to be associated with radiation, and the risk of death was higher if lymphoma was the initial diagnosis as a consequence of prior irradiation.

    20. Discipline

      Clinical Trials
      You have free access to this content
      Increasing accrual in cancer clinical trials with a focus on minority enrollment : The William Beaumont Hospital Community Clinical Oncology Program Experience (pages 4764–4771)

      Frank Vicini, Joyce Nancarrow-Tull, Chirag Shah, Gary Chmielewski, Monty Fakhouri, Stacey A. Sitarek, Claire T. Feczko, Carol Brzozowski and David L. Felten

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26094

      The development of a Community Clinical Oncology Program (CCOP) at William Beaumont Hospital in Royal Oak, Michigan, led to a significant increase in enrollment in clinical trials as well as the number of trials offered. With the creation of a minority outreach program in conjunction with a CCOP, minority enrollment in clinical trials doubled.

    21. Disparities Research
      You have free access to this content
      Acute myeloid leukemia : How the uninsured fare (pages 4772–4778)

      Cathy J. Bradley, Bassam Dahman, Yan Jin, Lisa M. Shickle and Gordon D. Ginder

      Version of Record online: 31 MAR 2011 | DOI: 10.1002/cncr.26095

      • original image

      This study addresses the urgency for health insurance that affords access to care. Without treatment, the outcome of acute myeloid leukemia is surely death within only a few months; with treatment, the chance for long-term remission or even cure exists.

    22. Diagnostic Imaging
      You have free access to this content
      18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma (pages 4779–4787)

      Beom Kyung Kim, Won Jun Kang, Ja Kyung Kim, Jinsil Seong, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Do Youn Lee, Kwang Hoon Lee, Jong Doo Lee and Kwang-Hyub Han

      Version of Record online: 5 APR 2011 | DOI: 10.1002/cncr.26099

      • original image
      • original image
      • original image

      Median progression-free survival (8.4 vs 5.2 months; P = .003), overall survival (17.9 vs 11.3 months; P = .013), and extrahepatic metastasis-free survival (13.8 vs 5.7 months; P < .001) were found to be significantly longer in subjects with low maximal tumor standardized uptake values (SUVs <6.1) than in those with high maximal tumor SUVs (≥6.1), in patients with locally advanced hepatocellular carcinoma (HCC) who underwent localized concurrent chemoradiation therapy. Similar results were obtained for the ratio of maximal tumor SUV to maximal normal liver SUV (<2 vs ≥2) concerning progression, death, and extrahepatic metastasis. Thus, tumor metabolic activity assessed by 18F-fluorodeoxyglucose uptake on positron emission tomography may be useful not only in predicting prognosis and treatment responses, but also in establishing optimal treatment plans in HCC patients.

    23. Pediatric Oncology
      You have free access to this content
      Treatment-related mortality in children with acute lymphoblastic leukemia in Central America (pages 4788–4795)

      Sumit Gupta, Federico A. Antillon, Miguel Bonilla, Ligia Fu, Scott C. Howard, Raul C. Ribeiro and Lillian Sung

      Version of Record online: 28 MAR 2011 | DOI: 10.1002/cncr.26107

      Rates of treatment-related mortality (TRM) were significantly higher in patients with acute lymphoblastic leukemia (ALL) in low-income countries compared with similar patients in high-income countries. In a cohort of children with ALL across 3 Central American countries, the authors observed that the timing, causes, and predictors of TRM were different in this population than in high-income settings, suggesting that different interventions are required to improve outcomes.

    24. Psychosocial Oncology
      You have free access to this content
      Full access to medical records does not modify anxiety in cancer patients : Results of a randomized study (pages 4796–4804)

      Gwenaelle Gravis, Cristel Protière, François Eisinger, Jean M. Boher, Carole Tarpin, Diane Coso, Maria-Antonietta Cappiello, Jacques Camerlo, Dominique Genre and Patrice Viens

      Version of Record online: 23 MAY 2011 | DOI: 10.1002/cncr.26083

      • original image

      Information is crucial, especially in malignant diseases. The objective of this study was to assess the impact of providing systematic full access to the medical record on anxiety, quality of life, and satisfaction. The results indicate that allowing full access to personal medical records increased satisfaction without increasing anxiety in newly diagnosed cancer patients.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION